| An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change. | None |
| Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. | None |
| Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. | None |
| Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. | None |
| Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. | None |
| The SH2 and catalytic domains of active Fes and Abl pro-oncogenic kinases form integrated structures essential for effective tyrosine kinase signaling. | None |
| Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. | None |
| The 5 non-coding region of the BCR/ABL oncogene augments its ability to stimulate the growth of immature lymphoid cells. | None |
| PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells. | None |
| Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide. | None |
| Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells. | None |
| The v-abl, c-fms, or v-myc oncogene induces gamma radiation resistance of hematopoietic progenitor cell line 32d cl 3 at clinical low dose rate. | None |
| This investigation establishes Abl as a potent mediator of mammary epithelial cell identity, and as a suppressor of oncogenic transforming growth factor-beta signaling during mammary tumorigenesis. | None |
| Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. | None |
| IL-3 and oncogenic Abl regulate the myeloblast transcriptome by altering mRNA stability | None |
| IL-3 and oncogenic Abl regulate the myeloblast transcriptome by altering mRNA stability. | None |
| Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. | None |
| reciprocal ABL/BCR fusion proteins as second oncogenes encoded by the t(9;22) in addition to BCR/ABL | None |
| c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3. | None |
| Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. | None |